Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 2,529–2,536 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Lyra Therapeutics Inc. LYR-220 - (BEACON) Chronic rhinosinusitis Phase 2 Clinical Pause Intranasal Respiratory
Lyra Therapeutics Inc. LYR-210 - (LANTERN) Chronic rhinosinusitis / Chronic Sinusitis Phase 2 Trial Discontinued Intranasal Respiratory
MacroGenics Inc. ZYNYZ (retifanlimab-dlwr) - (POD1UM-304) Non-small cell lung cancer (NSCLC) PDUFA Data Released Intravenous Oncology
MacroGenics Inc. MARGENZA (margetuximab) and MGA012 (MAHOGANY) Gastric cancer Phase 2/3 Intravenous Oncology
MacroGenics Inc. Retifanlimab Anal cancer Phase 2 Trial Completed Intravenous Oncology
MacroGenics Inc. MGC018 - (TAMARACK) Metastatic castration-resistant prostate cancer (mCRPC) Phase 2 Trial Discontinued Intravenous Oncology
MacroGenics Inc. Enoblituzumab Localized Prostate Cancer Phase 2 Ongoing Intravenous Oncology
MacroGenics Inc. Enoblituzumab, retifanlimab and tebotelimab Squamous cell carcinoma of the head and neck (SCCHN) Phase 2 Intravenous Oncology